Postnasal drip generally lasts for a few days or weeks, depending on the cause. If it becomes chronic, you may have it for months. Postnasal drip is usually diagnosed based on your symptoms and a ...

Chronic kidney failure, or end-stage kidney disease (ESKD), occurs when the kidneys no longer function effectively and cannot filter waste and extra fluid from the body. It is the fifth and final ...

This is particularly true for chronic diseases. For example, diabetes mellitus is defined biochemically according to the blood sugar concentration, cancer histologically according to the morphological ...

If you can’t avoid them altogether, there are several ways to deal with a chronic complainer. While everyone is negative sometimes, the constant pessimism from a chronic complainer can start ...

If action isn't taken now, Ontario's hospital system will not be able to cope with the influx of chronic illness cases in the next two decades, Anthony Dale, OHA president, told CBC Toronto.

About LYR-210 LYR-210 is an investigational product candidate for the treatment of chronic rhinosinusitis ... patients who have not undergone ethmoid sinus surgery. The company’s therapies ...

GSK an­nounced an­oth­er batch of pos­i­tive da­ta from its res­pi­ra­to­ry pro­gram with the in­ves­ti­ga­tion­al drug de­pemokimab, this time in pa­tients with chron­ic rhi ...

(IN BRIEF) GSK plc has announced positive results from its Phase III ANCHOR trials for depemokimab, a biologic treatment for chronic rhinosinusitis with nasal polyps (CRSwNP). The trials demonstrated ...

Depemokimab helped reduce nasal obstruction and polyp size for patients who have chronic rhinosinusitis with nasal polyps, a common condition that GSK said affects up to 4% of the population.

Depemokimab helped reduce nasal obstruction and polyp size for patients who have chronic rhinosinusitis with nasal polyps, a common condition that GSK said affects up to 4% of the population. Of those ...

Chronic rhinosinusitis with nasal polyps has caught the attention of drugmakers since U.S. approval of Sanofi and Regeneron Pharmaceuticals’ Dupixent in 2019. Abbreviated as CRSwNP, the condition ...

GSK Says Depemokimab For Chronic Rhinosinusitis Reduces Nasal Polyp Size, Nasal Obstruction Versus Placebo At One Year Vandana Singh Mon, Oct 14, 2024, 5:39 AM 2 min read ...